Navigation Links
Heart Drug Also Effective In Preventing Specific Causes Of Death

A drug commonly prescribed for people with high blood pressure and heart failure may also benefit those with other conditions that put them at higher risk for heart attacks and stroke. Researchers conducted a study among // about 9,000 men and women from the Heart Outcomes Prevention Evaluation (HOPE) study. All were 55 or older and suffering from heart-related problems other than heart failure, such as ischemic heart disease, nondebilitating stroke, peripheral arterial disease, or diabetes.

Originally, subjects were randomly assigned to take the angiotensin-converting enzyme inhibitor ramipril (Altace), vitamin E, or a placebo to see if either the ACE-inhibitor or vitamin E would prevent heart attacks or stroke. Vitamin E did not have any effect on heart attack or stroke rates, but ramipril showed a protective effect. Researchers took the study one step further to see if the drug would protect against two other conditions -- sudden cardiac death and nonfatal cardiac arrest. Compared to patients on the placebo, those taking ramipril were less likely to develop either condition: 3.3 percent vs. 4.2 percent. The participants were followed for about four and a half years.

Although ramipril was used exclusively in the study, researchers say they believe that other ACE-inhibitors would probably elicit similar results.
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
(Date:10/10/2008)...LE, PA The American Nurses Credentialing Center (...) as a Magnet hospital. The news came via a confer...taff who broke out with cheers and applause., GMC...itals and only 294 hospitals in the United States... hospitals are eligible for this recognition., "A...
(Date:10/10/2008)...ggests poor self-care partly to blame , ,...f Medicare beneficiaries who have diabetes, being ... according to a new study. , Publishing in th...l Medicine , researchers from the University of Wa...erage age of 75.6 years) who had diabetes and were...
(Date:10/10/2008)... Honoring excellence in the imple... Healthcare Information and Management Systems Soc...Davies Awards in the Organizational, Ambulatory an... Chicago, IL (PRWEB) October 1...on of electronic health records (EHRs), the Healt...
(Date:10/10/2008)...YORK, Oct. 10 /PRNewswire/ -- The Johns Hopkins Un...ultimedia educational program,"Optimizing Adjuvan...atment,Selection," to present recent key research ...ment., In recent years, advancements in the treat... and biologic treatment combinations that are,incr...
Breaking Medicine News(10 mins):Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2
...rcises can help restore erectile function in men, ...the University of the West of England in Bristol f...floor exercises had the same overall improvement a...elvic floor is made up of layers of muscle and oth...
...ered a gene mutation that may cause premature ovar...be useful for further study into, what researchers...ovarian failure is a form of infertility that affe...es. It is diagnosed in one out of every 100 women ...
...d allergy -- especially to peanuts -- has been sho...in children. Asthma attacks are the most common re...am Roberts from St. Mary's Hospital in London and ...n treatment, death due to childhood asthma has not...
...lacement therapy dosed to normalize IGF-I levels m...on in a "clinically necessary" weight loss program...ograms is to lose body fat but retain lean body ma... when people go on a diet, after a while, they sto...
Other Medicine News:Health News:Low-dose Growth Hormone (GH) with diet and exercise may help weight loss 2
(Date:10/8/2008)...view Zanolimumab Program to be Discontinued and He...he Results of its Portfolio Review; Zanolimumab P...uce the Number of Em...all/ -- Genmab A/S (OMX: GEN),announced today that...uMax-CD4(R)). In addition, as a result of a portfo...
(Date:10/8/2008)...SEUS clinical program to evaluate TAXUS(R) Element... Stent, NATICK, Mass., Oct. 8 /PRNewswire-Fir...SX ) today announced that it has completed enrollm... Company,s third-generation,TAXUS(R) Element(TM) p...ical program has enrolled nearly 1,500 patients at...
(Date:10/8/2008)... LYON, France, Oct. 8 /- Vical Incorp...ed clinical data and new nonclinical data,demonstr... be broadly,applicable in DNA- and protein-based i...r vaccines. Alain P. Rolland, Pharm.D., Ph.D., Vic... will present the data today,Wednesday, October 8...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Prometheus Labo... today announced findings from its,development of ...lood test,for irritable bowel syndrome (IBS). The ...ression of particular biomarkers in blood samples,...on of these biomarkers,combined with a proprietar...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Cancer cell line developed that is resistant to new cancer therapy 8043 1Cancer cell line developed that is resistant to new cancer therapy 8043 2New carbon calculator conserves forests 1542 1New carbon calculator conserves forests 1542 2Young Physicians Demanding Advanced Laparoscopic Energy Instruments 2130 1Young Physicians Demanding Advanced Laparoscopic Energy Instruments 2130 2Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference 2128 1Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference 2128 2
...inal Results from Exploratory Phase IIa Clinical T...O, June 28, 2007 /PRNewswire-FirstCall/ - Transiti...ces the results from,its exploratory Phase IIa cli...ments with gastrin-based therapy, E1-I.N.T.(TM), s...l parameters, including,haemoglobinA1C (HbA1c), fo...
...MARKHAM, ON, June 28, 2007 /PRNewswire/ - Cytochro... I clinical trial of,CTA018 Injection. The initial...18 was safe and well tolerated. Complete study,res...ompleted Phase I trial was an open label,placebo-...dministered to 20 healthy volunteers. In this tria...
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3
Heavy. 7.5 mm curved tip.
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1.
Size 4 - 2.25 mm
The Catalyst system introduces a new level of computer enhanced precision to microsurgical instrumentation. It has an easy to use digital design with advanced microcomputer control of modules and is
Medicine Products: